Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
Recombinant modified vaccinia virus Ankara expressing HIV-1 antigens (MVA.HIVA) was used in ELISpot assays to monitor HIV-1-specific T cell responses in infants. Responses to MVA.HIVA and HIV-1 peptides were examined in 13 infected and 81 exposed uninfected infants in Nairobi, Kenya. Responses to MVA.HIVA (38%) and peptide stimulation (38%) were similar in frequency (p=1.0) and magnitude (mean 176 versus 385 HIVSFU/10(6), p=0.96) in HIV-1 infected infants. In exposed uninfected infants, MVA.HIVA detected more positive responses and higher magnitude responses as compared to peptide. MVA.HIVA ELISpot is a sensitive method for quantification of HIV-1-specific CD8+ T cell responses in HIV-1 exposed infants. These results demonstrate the relevance of HIV-1 clade A consensus-derived immunogen HIVA for the viruses currently circulating in Nairobi.
Slyker
Jennifer A
JA
Department of Medical Microbiology, University of Nairobi, Kenya.
Lohman
Barbara L
BL
Mbori-Ngacha
Dorothy A
DA
Reilly
Marie
M
Wee
Edmund G-T
EG
Dong
Tao
T
McMichael
Andrew J
AJ
Rowland-Jones
Sarah L
SL
Hanke
Tomas
T
John-Stewart
Grace
G
D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D015488:HIV Antigens / Q000235:genetics / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000737:chemistry / Q000145:classification / Q000276:immunology*; D006801:Humans; D007223:Infant; D008213:Lymphocyte Activation / Q000276:immunology*; D014611:Vaccination; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology
D015488:HIV Antigens; D014765:Viral Vaccines